According to the broker, it is adjusting its price target as it starts to assign value to the company' induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy platform, or '500 series' of cell products. The broker said INDs have now cleared for FT500 and FT516, marking the first induced pluripotent stem cell (iPSC)-derived cell product and first engineered iPSC-derived product, respectively, to reach the clinic.
Price: 15.33, Change: +1.26, Percent Change: +8.93
|Avaya Surges 11% on Speculation of Rival Buyout Offe...|
|Correction: --(KSS) KOHLS CORP Q2 Total Revenue $4.43B|
|Correction: Kohl's Q2 Tops Estimates on EPS, Net Sal...|
|Clear Channel Outdoor Climbs 6% on More Insider Purc...|
|Market Chatter: Facebook's Libra Under Investigation...|